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Abstract  
 
Objective: To describe results of a systematic treatment program to modify renal 
and cardiovascular disease in an Aboriginal community whose rates of renal failure 
and cardiovascular deaths are among the highest in Australia. 
 
Design: Longitudinal survey of people during treatment, and comparison of rates of 
natural death and renal failure with those in a historical control group.  
 
Setting: Tiwi Islands (population, about 1800), November 1995 to December 1998. 
 
Participants: All adults with blood pressure 140/90, with diabetes and urinary 
albumin/creatinine ratio (ACR) 3.4 g/mol (microalbuminuria threshold), or with 
progressive overt albuminuria (ACR 34 g/mol) were eligible for treatment. The 
historical control group comprised 229 people who satisfied these criteria in the 
pretreatment period 1992-1995. 
 
Interventions: Perindopril, combined with calcium-channel blockers and diuretics if 
needed to achieve blood pressure goals; attempts to improve control of blood 
glucose and lipid levels; health education. 
 
Main outcome measures: Blood pressure, ACR, serum creatinine level and 
glomerular filtration rate (GFR) over two years of treatment; rates of renal failure and 
natural death compared with control group (analysed on intention-to-treat basis). 
 
Results: 258 people enrolled in the program, and 118 had complete data for two 
years of treatment. In these 118, blood pressures fell significantly, while ACR and 
GFR stabilised. Rates of the combined endpoints of renal failure and natural death 
per 100 person-years were 2.9 for the treatment group (95% CI, 1.7-4.6) and 4.8 for 
the control group (95% CI, 3.3-7.0). After adjustment for baseline ACR category, the 
relative risk of the treatment group versus the control group for these combined 
endpoints was 0.47 (95% CI, 0.25-0.86; P = 0.013). Treatment benefit was especially 
marked in people with overt albuminuria or hypertension and in non-diabetic people. 
The estimates of benefit were supported by a fall in community rates of death and 
renal failure. 
 
Conclusions: Aboriginal people can participate enthusiastically in chronic disease 
management, with rapid, dramatic improvement in clinical profiles and mortality. 
Similar programs should be introduced urgently into other Aboriginal communities 
nationwide. 
